Clinical Trial Update: Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 study evaluating brentuximab vedotin in combination with bendamustine in Hodgkin lymphoma have been posted after the trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Hodgkin Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-04-06